oxytia depot 80 mg depottablett
ethypharm uk ltd - oxikodonhydroklorid - depottablett - 80 mg - oxikodonhydroklorid 80 mg aktiv substans; laktosmonohydrat hjälpämne - oxikodon
valaciclovir bluefish 1000 mg filmdragerad tablett
bluefish pharmaceuticals ab - valaciklovirhydrokloridhydrat - filmdragerad tablett - 1000 mg - valaciklovirhydrokloridhydrat aktiv substans - valaciklovir
atomoxetin actavis 18 mg kapsel, hård
actavis group ptc ehf. - atomoxetinhydroklorid - kapsel, hård - 18 mg - propylenglykol hjälpämne; atomoxetinhydroklorid 20,57 mg aktiv substans
atomoxetin actavis 100 mg kapsel, hård
actavis group ptc ehf. - atomoxetinhydroklorid - kapsel, hård - 100 mg - propylenglykol hjälpämne; atomoxetinhydroklorid 114,3 mg aktiv substans
atomoxetin actavis 10 mg kapsel, hård
actavis group ptc ehf. - atomoxetinhydroklorid - kapsel, hård - 10 mg - propylenglykol hjälpämne; atomoxetinhydroklorid 11,43 mg aktiv substans
atomoxetin actavis 25 mg kapsel, hård
actavis group ptc ehf. - atomoxetinhydroklorid - kapsel, hård - 25 mg - propylenglykol hjälpämne; atomoxetinhydroklorid 28,58 mg aktiv substans
atomoxetin actavis 60 mg kapsel, hård
actavis group ptc ehf. - atomoxetinhydroklorid - kapsel, hård - 60 mg - atomoxetinhydroklorid 68,58 mg aktiv substans; propylenglykol hjälpämne
atomoxetin actavis 80 mg kapsel, hård
actavis group ptc ehf. - atomoxetinhydroklorid - kapsel, hård - 80 mg - propylenglykol hjälpämne; atomoxetinhydroklorid 91,44 mg aktiv substans
atomoxetin actavis 40 mg kapsel, hård
actavis group ptc ehf. - atomoxetinhydroklorid - kapsel, hård - 40 mg - propylenglykol hjälpämne; atomoxetinhydroklorid 45,72 mg aktiv substans
lacosamide accord
accord healthcare s.l.u. - lakosamid - epilepsi - antiepileptika, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy• in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.